Malignant mesothelioma
Knowledge about some aspects of malignant mesothelioma has increased in recent years, but sadly effective treatment still eludes us and the progxiosis remains very poor.
The tumour arises from mesothelial cells or possibly from more primitive submesothelial cells. It occurs most commonly in the pleura or peritoneum but, rarely, may arise in the pericardium or tunica vaginalis testis.
The existence of primary.mesothelial tumours was not generally accepted until the late 1950s although reports of pleural and peritoneal tumours can be recognized much earlier. In 1960 Wagner and colleagues described 33 cases of diffuse pleural mesothelioma and all but one had experienced probable exposure to crocidolite (blue asbestos)'. Subsequently it came to be recognized that occupational asbestos exposure is responsible for most cases. Among subjects without exposure the annual incidence is probably around 1 to 2 per million2. A few childhood cases, apparently unrelated to exposure to asbestos or other fibrous minerals have occurred3.
Deaths from mesothelioma, currently more than 600 per year in the UK, are still rising here and in other industrial countries. The increase is likely to continue until the turn of the century, reflecting the increasing use of asbestos, with inadequate or nonexistent respiratory protection, until about 1970. In heavily exposed populations more than 10% of subjects may die of mesothelioma4. The tumour is commoner in males, reflecting the greater frequency with which they have been exposed to asbestos.
Naturally occurring mineral fibres also cause mesothelioma. Endemic pleural mesothelioma in Karain, a remote village in central Turkey was reported in 19785. Mesothelioma accounted for the majority of adult deaths and the youngest patient was aged 126. The materials responsible were found to be a fibrous zeolite called erionite and possibly other environmental asbestos minerals present in the volcanic tuff which is quarried and used for building. Naturally occurring tremolite, and perhaps chrysotile, cause mesothelioma in Cyprus7 and Greece8.
Glass fibres can cause mesothelioma in animals9 and concern arose that asbestos substitutes might lead to mesothelioma in man. Fortunately, commercially used man-made mineral fibres are mostly of much larger dimensions than those used experimentally and a study of 25 000 workers engaged in their manufacture found only one of 1505 deaths to be due to mesothelioma'0.
There are no ideal studies that. report the dosespecific mesothelioma risk based on individual exposure estimates but several studies have shown that the risk of mesothelioma increases with cumUiltive exposure'1-'3. Animal studies confirm this relation14. Cases of pmesothelioma attributable to hiome or neighbourhood exposure have been identified'5 and this had led to the widely held belief that even trivial exposure to asbestos is associated -with a substantial risk of mesothelioma. However, such cases occurred among a huge population of persons exposed in this way and the risk associated with 'low-level or brief exposure is very small'617.
The incidence of mesothelioma increases with time elapsed since first exposure to asbestos in proportion the third or fourth power of the time elapsed'8. The relative risk is not related to age at first exposure, although the absolute risk is greater with earlier exposure because there is more time for mesothelioma to develop. The risk of mesothelioma is not affected by smoking.
In a UK study of cases from various sources, in which 85% of those for whom information was available'had definite or possible asbestos exposure, the mean interval from onsetofexposure to death was 38 years with a range of 3.5-53 years'9. Intervals of less tuan 20 years were uncomkQn in this, as in other series. The long interval between exposure and death 0141-0768/89/ 030126-04402.00/0 i 1989 The Royal Society of Medicine does not imply that the tumour has been growing throughout the latent period. Because of its location and mode of growth the doubling time ofmesothelioma is difficult to determine directly. The doubling time for lung cancer is easier to determine from serial chest X-rays and it has been calculated that the period between commencement of growth of a tumour and the onset of clinical manifestations probably averages about 10 years20. The interval between the onset of clinical manifestations and death is approximately similar for lung cancer and mesothelioma and it is reasonable to assume that mesothelioma also starts to grow about 10 years on average before clinical manifestations appear. This assumption fits the epidemiological data well18.
Assessment of the effects of fibre type has been difficult because most workers have been exposed to a mixture of the commercial types. Nevertheless, the weight of the evidence suggests that amphiboles are more potent than chrysotile in causing mesothelioma and that among the amphiboles, crocidolite is more potent than amosite16. It has been suggested that mesothelioma in workers exposed only to chrysotile may have been due to small quantities of a contaminating amphibole, tremolite21. However, animal experiments confirm that chrysotile alone can cause mesotheliomal4.
Differences in fibre dimension probably account for the higher risk associated with the long thin amphibole fibres compared with the curly chrysotile fibres. In animal experiments samples offibrous glass less than 1.5 zm in diameter and longer than 8 ym were more potent than other sizes in producing pleural sarcomas9. The fibre shape may determine the chance of a fibre reaching the pleura and its propensity to initiate malignant transformation in cells with which it makes contact.
It is not known how asbestos fibres reach the pleura or peritoneum. Fibres probably work their way through the lungs to penetrate the visceral pleura and then reach the parietal pleura by direct penetration or via the lymphatics. Fibres may be transported in the lymphatics from the lungs to the abdomen where they have been found in lymph nodes and other abdominal organs22. Asbestos fibres are also transported across the mucosa of the intestinal tract after ingestion23.
Asbestos is a complete carcinogen for mesothelioma; no agent other than fibrous structures has been identified as a cause of the tumour in man. The mechanism of malignant transformation is not known for certain but there is evidence that chromosomal damage including deletions, perhaps as a direct physical effect of penetration of the nucleus by long thin fibres, may be involved24 25. It has been suggested that foreign body carcinogenesis may be relevant to the pathogenesis of the disease26. However, there are many important differences between this experimental model, in which sarcomas can be induced in the skin ofrodents by implantation of a single sheet of metal, glass or other material, and mesothelioma, in which the presence oflarge numbers of long thin fibres is important.
It is probable that the pathogenesis of the tumour involves a series of genetic or epigenetic accidents18.
The initiation stage may occur many times and the process may then be aborted many times, for example by repair or death of the cell affected. It is also probable that pathogenesis is multi-stage; after the initial transformation further events may be necessary for multiplication of the cell to commence. The relationship between dose of asbestos and risk of mesothelioma may result from a greater likelihood of a transformed cell surviving and eventually multiplying to form a tumour when a greater number of asbestos fibres affects a greater number of cells.
It has. also been suggested that asbestos may act as a promoter of mesothelioma27. Impairment of lymphatic clearance of asbestos fibres by fibrosis27, and impairment of non-specific defence mechanisms against malignant disease, for example alterations in lymphocyte sub-populations in the lunge and reduced activity of natural killer cells, may be relevant29.
The main histological varieties are the epithelial, sarcomatous and mixed patterns. Direct extension is commoner with epithelial tumours though it occurs commonly with all types. In a series of 115 cases large pleural effusions occurred in over 70% of both epithelial and mixed tumours, but in only 16% ofthe sarcomatous tumours3O. In 60 of the cases in which autopsies were performed distant metastases occurred in 37% of epithelial tumours, 33% of mixed tumours and 78% of sarcomatous tumours. Those with epithelial tumours tend to survive a little longer than those with mixed or sarcomatous tumours31 .
Asbestos bodies are usually found in the lung tissue though not in the tumour tissue. Electron microscopy usually demonstrates some uncoated fibres in the tumour tissue. In lung tissue fibre counts are usually within the range seen in occupationally exposed individuals, although on average, lower than in cases of asbestosis32.
Cytological examination of the fluid has a sensitivity of 25-62% depending upon the experience of the laboratory and cytologist in preparation and interpretation of samples33. The frequency of definite diagnosis by percutaneous needle biopsy is low, reported at 39% in one series33 and 59%o in another34.
Ifthe pleura is grossly thickened larger samples may be obtained by Tru-cut biopsy or by trephine biopsy. The latter method obtains the largest samples and may allow a positive diagnosis after other percutaneous techniques have been unsuccessfulw. Trephine biopsy also has a lower risk of tumour seeding in the biopsy track, perhaps because the core of biopsy material is contained within a metal cylinder. Biopsies may be obtained under direct vision at thoracoscopy which may be performed under local anaesthesia36. As a last resort thoracotomy may be undertaken but the diagnosis occasionally still remains in doubt because ofthe nature ofthe tumour.
Interpretation of histological features is notoriously diffilcult and there is considerable inter-observer disagreement in the histological diagnosis of meso-thelioma37. The main problems are the differentiation between mesothelioma and secondary adenocarcinoma of the pleura, usually of pulmonary origin, and the separation of benign from malignant pleural disease32. Normal mesothelial cells react to a variety of stimuli by mitotic activity, resulting in the development of rounded cells which float off the normal pavement layer of flattened cells. Papillary or pseudoacinar structures may be formed and it may be impossible to distinguish benign from malignant changes on purely morphological grounds. Histochemical and immunohistochemical methods improve the accuracy of histological diagnosis.
Histochemical and immunohistochemical methods improve the accuracy of histological diagnosis. Epithelial and mixed types of mesothelioma produce acid mucosubstances containing hyaluronic acid, which is present in the cytoplasm of epithelial elements as secretory vacuoles and in the tubular lumens. Adenocarcinomas produce neutral and acid mucosubstances but little or no hyaluronic acid. The periodic acid Schiff-diastase method for neutral mucosubstances usually gives negative results with mesothelioma but is positive in about 50% of adeno-carcinomas38. About one third to one half of mesotheliomas produce sufficient hyaluronic acid to give a positive reaction with Alcian blue which may be eliminated by pretreatment with hyaluronidase. The latter does not affect the positive reaction due to acid mucopolysaccharides produced by adenocarcinoma38.
Carcino-embryonic antigen (CEA) is usually positive in adenocarcinoma and negative in mesothelioma3948. This is the most clinically useful immunohistochemical method. Mesotheliomas usually stain positively for keratin proteins while adenocarcinomas are more commonly negative41, but the diagnostic value of this distinction has been low in some hands42. Some mesotheliomas stain positively for vimentin, the intermediate filament considered characteristic of mesenchymal cells43.
The distinction between reactive and malignant mesothelial change is often difficult. Stains for epithelial membrane antigens, human milk fat globule (HMFG) 1 and 2, are usually negative in benign reactive mesothelium, and positive in both mesothelioma and adenocarcinoma39. However, results are dependent upon methodology and another group ground that mesotheliomas were negative for HMFG244. Reactive mesothelial cells are usually positive for alpha-1-antichymotypsin, while carcinoma and mesothelioma cells are usually negative45.
Electron microscopy allows identification of ultrastructural features characteristic of malignancy'8.
Karyotype analysis may also be used to distinguish benign from malignant epithelial proliferation. Treatment remains unsatisfactory. There are reports of occasional good results from radical surgery for limited disease, from radiotherapy and from chemo-therapy3l. Some benefit has been reported from surgical debulking ofperitoneal mesothelioma followed by combination chemotherapy and radiotherapy47. Doxorubicin, the chemotherapeutic agent best documented to show activity, produces objective responses in less than 20% of cases'8. Preliminary experience with carboblatin suggests activity in about 20% of cases49.
Unfortunately, few studies have included a control group and there is no convincing evidence that treatment improves upon the average survival from diagnosis of about 18 months5O. As illustrated by a case described in this issue (Lockwood, p. 168) occasional patients survive considerably longer than average, some more than five years30 and anecdotal reports of prolonged survival cannot be relied upon as proof of efficacy of treatment.
New approaches are undergoing evaluation. The injection into the pleural cavity of a source of radiation linked to monoclonal antibodies specific for tumour cells probably has potential only in early disease where the layer of tumour is thin enough for the radiation to penetrate to the deeper parts from the surface. The use offastneutrontherapy may have potential51, but few centres have a cyclotron, needed for this modality.
Symptomatic treatment is worthwhile. Pleural aspiration and chemical pleurodesis, for example with intrapleural tetracycline, are useful for recurrent pleural effusion. In this issue some benefit in reduction of fluid accumulation and pain relief is described from the use of phenol irrigation and this merits further evaluation. Sclerosing therapy may also be attempted for recurrent gross ascites although the risk of provoking symptomatic adhesions must be weighed against possible benefit.
Conventional radiotherapy may provide pain relief but results are often disappointing unless there is a localized area of pain for example, due to invasion of a nerve root, rib or vertebra. Transcutaneous electrical stimulation of nerves and nerve blocks are occasionally helpful. Opiates remain the mainstay of treatment in the later stages of the disease.
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